Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | July 29, 2016 | July 29, 2016 |
| AbbVie Inc.ABBV · Entity 2800 | Director | May 08, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date July 29, 2016 · Filed July 29, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 395,819 |
Ending reported balance
After 2016-07-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-07-29 · Exercise / conversion · Acquired 56,000 · Balance 438,682 Row 2 · 2016-07-29 · Tax withholding · Disposed 42,863 · Balance 395,819 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.25 · Expires 2017-02-15 | Direct | 0 |
Reported balance
After 2016-07-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2016-07-29 · Exercise / conversion · Disposed 56,000 · Balance 0 F6: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,130 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,130 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of July 28, 2016. |
| Common shares without par valueSEC Table I · non-derivative | IndirectAnnette Newton-Freyman 1994 Trust | 4,000 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,000 F2: Held in the Annette Newton-Freyman 1994 Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities. |
| Common shares without par valueSEC Table I · non-derivative | IndirectAnnette Newton-Freyman 2012 Irrevocable Trust | 76,000 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 76,000 F3: Held in the Annette Newton-Freyman 2012 Irrevocable Trust. The reporting person is trustee of the trust. The trust is irrevocable. The reporting person disclaims beneficial ownership of these securities. |
| Common shares without par valueSEC Table I · non-derivative | IndirectThomas C. Freyman 2012 Irrevocable Trust | 76,000 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 76,000 F4: Held in the Thomas C. Freyman 2012 Irrevocable Trust. The reporting person's spouse is trustee of the trust. The trust is irrevocable. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy spouse as trustee for son | 1,941 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 1,941 F5: These shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy spouse as trustee for son | 1,941 |
Reported balance
Holding disclosure · report date 2016-07-29 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 1,941 F5: These shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of July 28, 2016.
F2: Held in the Annette Newton-Freyman 1994 Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.
F3: Held in the Annette Newton-Freyman 2012 Irrevocable Trust. The reporting person is trustee of the trust. The trust is irrevocable. The reporting person disclaims beneficial ownership of these securities.
F4: Held in the Thomas C. Freyman 2012 Irrevocable Trust. The reporting person's spouse is trustee of the trust. The trust is irrevocable.
F5: These shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities.
F6: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
AbbVie Inc.
Report date May 08, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 127,869 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Grant · Acquired 1,118 · Balance 127,869 F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust | 4,000 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,000 F2: The reporting person's spouse is the trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust for son | 1,941 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,941 F3: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust for son | 1,941 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,941 F3: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2: The reporting person's spouse is the trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.
F3: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allergan plc
Report date May 08, 2020 · Filed May 12, 2020
Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-08 · Disposition to issuer · Disposed 2,983 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
HANGER, INC.
Report date October 03, 2022 · Filed October 04, 2022
Section 16 reporting ended · disclosed 2022-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 43,561 · Balance 0 F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash.
TENNECO INC
Report date November 17, 2022 · Filed November 21, 2022
Section 16 reporting ended · disclosed 2022-11-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-17 transaction · row 1
1 source rowRow 1 · 2022-11-17 · Disposition to issuer · Disposed 93,892 · Balance 0 F1: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub, upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition upon completion of the merger (the "Merger") of Pegasus Merger Co. ("Merger Sub"), a wholly owned subsidiary of Pegasus Holdings III, LLC ("Parent"), with and into the Issuer, effective November 17, 2022. Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2022, by and among the Issuer, Parent and Merger Sub, upon completion of the Merger, each outstanding share of the Issuer's Class A Common Stock was converted into the right to receive $20.00 per share in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 21, 2013 Filed Oct 23, 2013 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 42,487 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001179110-13-015717 · edgar.xml · derivative · entry 10 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 42,487 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 21, 2013 Filed Oct 23, 2013 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 41,059 | $37.29 | $1,531,090.11 |
DisclosureSEC source: 0001179110-13-015717 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,224 Read SEC document |
| October 21, 2013 Filed Oct 23, 2013 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 42,487 | $34.93 | $1,484,070.91 |
DisclosureSEC source: 0001179110-13-015717 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2013 Filed Apr 3, 2013 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 63,800 | $0.00 Strike: $22.27 | $0.00 |
DisclosureSEC source: 0001179110-13-006380 · edgar.xml · derivative · entry 10 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 63,800 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 01, 2013 Filed Apr 3, 2013 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 50,917 | $35.32 | $1,798,388.44 |
DisclosureSEC source: 0001179110-13-006380 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,796 Read SEC document |
| April 01, 2013 Filed Apr 3, 2013 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 63,800 | $22.27 | $1,420,634.60 |
DisclosureSEC source: 0001179110-13-006380 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2013 Filed Mar 14, 2013 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 42,487 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001179110-13-005141 · edgar.xml · derivative · entry 13 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,487 Underlying: Common shares · 42,487 shares Expires 2014-02-19 F7 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 12, 2013 Filed Mar 14, 2013 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 16,384 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001179110-13-005141 · edgar.xml · derivative · entry 12 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 16,384 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 12, 2013 Filed Mar 14, 2013 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 33,180 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001179110-13-005141 · edgar.xml · derivative · entry 11 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 33,180 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 12, 2013 Filed Mar 14, 2013 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 42,487 | $34.93 | $1,484,070.91 |
DisclosureSEC source: 0001179110-13-005141 · edgar.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,913 Read SEC document |
| March 12, 2013 Filed Mar 14, 2013 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 16,384 | $26.09 | $427,488.05 |
DisclosureSEC source: 0001179110-13-005141 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2013 Filed Mar 14, 2013 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 33,180 | $25.25 | $837,824.86 |
DisclosureSEC source: 0001179110-13-005141 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2013 Filed Mar 2, 2013 00:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 28,188 | $34.26 | $965,720.88 |
DisclosureSEC source: 0001179110-13-003898 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,836 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 15,024 | $35.08 | $527,041.92 |
DisclosureSEC source: 0001179110-13-003136 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,024 Read SEC document |
| February 15, 2013 Filed Feb 20, 2013 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 299,300 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-13-003136 · edgar.xml · derivative · entry 10 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,300 Underlying: Common shares · 299,300 shares Expires 2023-02-14 F8 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 99,767 on 2/15/2014, 99,766 on 2/15/2015, and 99,767 on 2/15/2016. Read SEC document |
| February 15, 2013 Filed Feb 20, 2013 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 57,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-003136 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,048 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| November 16, 2012 Filed Dec 14, 2012 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 76,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-017665 · edgar.xml · nonDerivative · entry 6 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Thomas C. Freyman 2012 Irrevocable Trust Disclosed balance after: 76,000 F3 · balance_after: Held in the Thomas C. Freyman 2012 Irrevocable Trust. The reporting person's spouse is trustee of the trust. The trust is irrevocable by the reporting person. Read SEC document |
| November 16, 2012 Filed Dec 14, 2012 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 76,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-017665 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,548 Read SEC document |
| November 13, 2012 Filed Dec 14, 2012 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 76,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-017665 · edgar.xml · nonDerivative · entry 5 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Annette Newton Freyman 2012 Irrevocable Trust Disclosed balance after: 76,000 F2 · balance_after: Held in the Annete Newton Freyman 2012 Irrevocable Trust. The reporting person is trustee of the trust. The trust is irrevocable by the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| November 13, 2012 Filed Dec 14, 2012 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 76,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-017665 · edgar.xml · nonDerivative · entry 4 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Annette Newton-Freyman 1994 Trust Disclosed balance after: 4,000 F1 · balance_after: Held in the Annette Newton-Freyman 1994 Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| November 08, 2012 Filed Dec 14, 2012 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-017665 · edgar.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Annette Newton-Freyman 1994 Trust Disclosed balance after: 80,000 F1 · balance_after: Held in the Annette Newton-Freyman 1994 Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| November 08, 2012 Filed Dec 14, 2012 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-017665 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,548 Read SEC document |
| September 21, 2012 Filed Sep 25, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001179110-12-014492 · edgar.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common shares · 30,000 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 21, 2012 Filed Sep 25, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 23,538 | $69.86 | $1,644,364.68 |
DisclosureSEC source: 0001179110-12-014492 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,548 Read SEC document |
| September 21, 2012 Filed Sep 25, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 30,000 | $44.16 | $1,324,800.00 |
DisclosureSEC source: 0001179110-12-014492 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2012 Filed Jul 25, 2012 21:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001179110-12-011782 · edgar.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common shares · 30,000 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 23, 2012 Filed Jul 25, 2012 21:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 24,357 | $65.06 | $1,584,666.42 |
DisclosureSEC source: 0001179110-12-011782 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,086 Read SEC document |
| July 23, 2012 Filed Jul 25, 2012 21:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 30,000 | $44.16 | $1,324,800.00 |
DisclosureSEC source: 0001179110-12-011782 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2012 Filed May 4, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 25,602 | $0.00 Strike: $58.90 | $0.00 |
DisclosureSEC source: 0001179110-12-007791 · edgar.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 25,602 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 03, 2012 Filed May 4, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 24,705 | $62.65 | $1,547,768.25 |
DisclosureSEC source: 0001179110-12-007791 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,443 Read SEC document |
| May 03, 2012 Filed May 4, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 25,602 | $58.90 | $1,507,957.80 |
DisclosureSEC source: 0001179110-12-007791 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2012 Filed Mar 22, 2012 21:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 25,701 | $0.00 Strike: $54.67 | $0.00 |
DisclosureSEC source: 0001179110-12-005621 · edgar.xml · derivative · entry 11 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 25,701 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 20, 2012 Filed Mar 22, 2012 21:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 26,572 | $0.00 Strike: $52.55 | $0.00 |
DisclosureSEC source: 0001179110-12-005621 · edgar.xml · derivative · entry 10 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 26,572 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 20, 2012 Filed Mar 22, 2012 21:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 24,314 | $60.22 | $1,464,189.08 |
DisclosureSEC source: 0001179110-12-005621 · edgar.xml · nonDerivative · entry 4 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,546 Read SEC document |
| March 20, 2012 Filed Mar 22, 2012 21:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 24,590 | $60.22 | $1,480,809.80 |
DisclosureSEC source: 0001179110-12-005621 · edgar.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,860 Read SEC document |
| March 20, 2012 Filed Mar 22, 2012 21:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 25,701 | $54.67 | $1,405,073.67 |
DisclosureSEC source: 0001179110-12-005621 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2012 Filed Mar 22, 2012 21:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 26,572 | $52.55 | $1,396,358.60 |
DisclosureSEC source: 0001179110-12-005621 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 27,207 | $57.04 | $1,551,887.28 |
DisclosureSEC source: 0001179110-12-004075 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,177 Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 22:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 107,300 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003232 · edgar.xml · derivative · entry 7 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,300 Underlying: Common shares · 107,300 shares Expires 2022-02-16 F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 35,767 on 02/17/2013, 35,766 on 02/17/2014, and 35,767 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 22:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 59,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003232 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,384 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| December 21, 2011 Filed Dec 23, 2011 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 95,764 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-11-017129 · edgar.xml · derivative · entry 8 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 95,764 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 21, 2011 Filed Dec 23, 2011 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 94,483 | $54.86 | $5,183,337.38 |
DisclosureSEC source: 0001179110-11-017129 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,984 Read SEC document |
| December 21, 2011 Filed Dec 23, 2011 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 95,764 | $53.63 | $5,135,344.50 |
DisclosureSEC source: 0001179110-11-017129 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2011 Filed Aug 9, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,200 | $49.19 | $501,748.20 |
DisclosureSEC source: 0001179110-11-011939 · edgar.xml · nonDerivative · entry 5 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,703 Read SEC document |
| August 05, 2011 Filed Aug 9, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $49.19 | $4,919.09 |
DisclosureSEC source: 0001179110-11-011939 · edgar.xml · nonDerivative · entry 4 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,903 Read SEC document |
| August 05, 2011 Filed Aug 9, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $49.19 | $4,919.03 |
DisclosureSEC source: 0001179110-11-011939 · edgar.xml · nonDerivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,003 Read SEC document |
| August 05, 2011 Filed Aug 9, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $49.19 | $4,919.02 |
DisclosureSEC source: 0001179110-11-011939 · edgar.xml · nonDerivative · entry 2 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,103 Read SEC document |
| August 05, 2011 Filed Aug 9, 2011 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,500 | $49.19 | $467,305.00 |
DisclosureSEC source: 0001179110-11-011939 · edgar.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,203 Read SEC document |
| May 09, 2011 Filed May 11, 2011 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $52.44 | $15,732.00 |
DisclosureSEC source: 0001179110-11-007802 · edgar.xml · nonDerivative · entry 21 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,703 Read SEC document |
| May 09, 2011 Filed May 11, 2011 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $52.44 | $31,461.00 |
DisclosureSEC source: 0001179110-11-007802 · edgar.xml · nonDerivative · entry 20 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,003 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.